La Jolla Pharmaceutical Co. (NASDAQ:LJPC)’s share price dropped 4.4% on Tuesday . The stock traded as low as $15.55 and last traded at $15.65, with a volume of 59,510 shares trading hands. The stock had previously closed at $16.37.

LJPC has been the topic of several recent analyst reports. SunTrust Banks Inc. started coverage on La Jolla Pharmaceutical in a research note on Wednesday, June 22nd. They set a “buy” rating and a $30.00 price objective on the stock. Jefferies Group reiterated a “buy” rating on shares of La Jolla Pharmaceutical in a research note on Wednesday, June 8th. Lake Street Capital started coverage on La Jolla Pharmaceutical in a research note on Tuesday, May 24th. They set a “buy” rating and a $25.00 target price on the stock. Finally, Zacks Investment Research upgraded La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Tuesday, July 12th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $39.50.

The stock’s 50 day moving average price is $16.71 and its 200 day moving average price is $17.74. The stock’s market cap is $285.86 million.

La Jolla Pharmaceutical (NASDAQ:LJPC) last posted its quarterly earnings data on Friday, May 6th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by $0.22. On average, equities analysts anticipate that La Jolla Pharmaceutical Co. will post ($3.99) earnings per share for the current fiscal year.

An institutional investor recently raised its position in La Jolla Pharmaceutical stock. P.A.W. Capital Corp boosted its position in La Jolla Pharmaceutical Co. (NASDAQ:LJPC) by 5.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 50,400 shares of the biopharmaceutical company’s stock after buying an additional 2,400 shares during the period. La Jolla Pharmaceutical makes up 1.5% of P.A.W. Capital Corp’s holdings, making the stock its 28th largest position. P.A.W. Capital Corp owned 0.28% of La Jolla Pharmaceutical worth $1,361,000 at the end of the most recent reporting period.

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It is engaged in the research, development and commercialization of its technologies and drug candidates for pharmaceutical products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.